To Toci or Not to Toci for Coronavirus Disease 2019 (COVID-19): Is That Still the Question?

Guang-Shing Cheng^{1

2}, Joshua A Hill^{2

3

4}

Affiliations

¹ Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, Washington, USA.
² Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
³ Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
⁴ Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.

Editorial

Guang-Shing Cheng et al. Clin Infect Dis. 2021.

. 2021 Jul 15;73(2):e455-e457.

doi: 10.1093/cid/ciaa1133.

Guang-Shing Cheng^{1

2}, Joshua A Hill^{2

3

4}

¹ Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, Washington, USA.
² Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
³ Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
⁴ Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.

No abstract available

Keywords: COVID-19; SARS-CoV-2; coronavirus; immunomodulatory; tocilizumab.

Comment on

Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19.
Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, Zhou N, Petty LA, Baang JH, Dillman NO, Frame D, Gregg KS, Kaul DR, Nagel J, Patel TS, Zhou S, Lauring AS, Hanauer DA, Martin E, Sharma P, Fung CM, Pogue JM. Somers EC, et al. Clin Infect Dis. 2021 Jul 15;73(2):e445-e454. doi: 10.1093/cid/ciaa954. Clin Infect Dis. 2021. PMID: 32651997 Free PMC article.